text stringlengths 1 5.46k |
|---|
Charles River Discovery Research Services UK Ltd<br>Manston Road<br>Margate<br>Kent, CT9 4LT<br>Great Britain |
Charles River Disc. Research Services Finland Ltd<br>Microkatu 1<br>70210 Kuopio<br>Finland |
Charnwood Molecular Ltd<br>The Heritage Building, 7 Beaumont Court<br>Prince William Road<br>LOUGHBOROUGH, LE11 5GA<br>Leicestershire<br>Great Britain |
Concept Life Sciences Integrated Disc & Develop<br>Frith Knoll Road<br>Chapel-en-le-Frith<br>High Peak, SK23 0PG<br>Great Britain |
Covance Laboratories Ltd<br>Otley Road<br>Harrogate<br>N Yorkshire, HG3 1PY<br>Great Britain |
Crown Bioscience Inc<br>3375 Scott Blvd<br>Suite 108<br>Santa Clara<br>CA 95054<br>United States |
Cyprotex Discovery Ltd<br>15 Beech Lane<br>MACCLESFIELD, SK10 2DR<br>Cheshire<br>Great Britain |
DiscoveRX Corporation Ltd<br>Faraday Wharf, Holt Street<br>Birmingham Science Park, Aston<br>BIRMINGHAM, B7 4BB<br>Great Britain |
Eurogentec Ltd<br>Old Headmasters House<br>Unit 1, Building 1<br>Forest Business Centre<br>Fawley Road, Fawley<br>Southampton<br>Hampshire<br>SO45 1FJ |
Fisher Scientific<br>Finance Department<br>Bishop Meadow Road<br>LOUGHBOROUGH, LE11 5RG<br>Leicestershire<br>Great Britain |
Horizon Discovery Group<br>Building 7100<br>Cambridge Research Park<br>Cambridge<br>CB25 9TL |
Onyx Scientific Ltd<br>Units 97/98<br>Silverbriar, Sunderland Enterprise Park East<br>Sunderland, SR5 2TQ<br>Great Britain |
Sequani Limited<br>Bromyard Road<br>LEDBURY, HR8 1LH<br>Great Britain |
South Bay Bio LLC<br>5941 Optical Ct, STE 229<br>San Jose CA,<br>95138 |
Syncom BV<br>PO Box 2253<br>9704 CE Groningen<br>Netherlands |
Ubiquigent<br>Sir James Black Centre<br>Dow Street<br>Dundee<br>DD1 5EH |
XenoGesis Ltd<br>BioCity Nottingham<br>Pennyfoot Street<br>NOTTINGHAM, NG1 1GF<br>Great Britain |
Schedule 1.179<br>Suitable Biochemical Assays |
The Suitable Biochemical Assays are assays for each of the DUBs set out below. The protocol for each Suitable Biochemical Assay is as disclosed in the Mission data room made available to AbbVie on or prior to the Effective Date |
Agreed Assays (as set forth on Schedule 1.15), plus: |
ATXN3L<br>CYLD<br>OTUB2<br>OTUD1<br>OTUD5<br>OTUD6A<br>OTUD6B<br>SENP1<br>SENP6<br>UCHL5<br>USP11<br>USP13<br>USP16<br>USP19<br>USP2<br>USP25<br>USP36<br>USP5<br>USP51<br>USP6<br>USPL1<br>VCPIP |
Schedule 4.9<br>Form of Confirmatory License Agreement |
CONFIRMATORY PATENT LICENSE |
THIS AGREEMENT is made the ___________day of______________________20[●] |
1) MISSION THERAPEUTICS LIMITED, a company registered in England and Wales having a place of business at McClintock Building, Granta Park, Great Abington, Cambridge CB21 6GP, England ("Mission"); and |
2) [ABBVIE BIOTECHNOLOGY LTD], a corporation organized under the laws of Bermuda whose address is Clarendon House, 2 Church Street, Hamilton HM11, Bermuda ("AbbVie"). |
RECITALS: |
By an agreement (the "Main Agreement") dated __________________ and made between Mission and AbbVie, Mission agreed for the consideration therein contained, among other things, to grant to AbbVie a licence under [Country/region Patent No.__________] (the "Patent") of which this Agreement is a confirmatory licence. |
OPERATIVE PROVISIONS: |
1. In pursuance of the Main Agreement and for the consideration referred to in the Main Agreement Mission hereby grants to AbbVie an exclusive licence under the Mission Patents from the ________ day of_____________ 20___ to research, develop, use, keep, make, have made, import, sell and otherwise dispose of Licensed Pr... |
2. Subject to the provisions of the Main Agreement this Agreement shall terminate without notice in the event of the termination for any reason of the Main Agreement. |
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives effective as of the Effective Date. |
ABBVIE BIOTECHNOLOGY LTD MISSION THERAPEUTICS LIMITED |
By: _________________ By: _________________<br>Name: _________________ Name: _________________<br>Title: _________________ Title: _________________ |
Schedule 8.6<br>Form of Press Release |
Mission Therapeutics and AbbVie sign DUBs Collaboration in Alzheimer's and Parkinson's Disease |
Collaboration combines Mission's unique science, chemistry and proprietary enzyme platform with AbbVie's strong neurodegenerative disease research, development and commercialisation capabilities |
CAMBRIDGE, UK and NORTH CHICAGO, ILL, USA – X November 2018 – Mission Therapeutics ("Mission"), a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) and AbbVie ("AbbVie")(NYSE: ABBV), a research-based global biopharmaceutical company, today announced a collaboration ... |
Alzheimer's and Parkinson's diseases are associated with the accumulation of misfolded, toxic proteins, which are believed to cause impaired function and death of nerve cells in the brain. DUBs play an important role in keeping a cell healthy by regulating the degradation of these proteins. There are over 100 different... |
Alzheimer's and Parkinson's disease are the most common forms of neurological disorders. In 2017, an estimated 50 million people were living with dementia and Alzheimer's disease; this number is expected to double every 20 years, reaching 75 million by 2030. More than 10 million people worldwide are living with Parkins... |
Dr James B Summers, Vice President, Neuroscience Discovery Research, AbbVie said: "There is an urgent need for new treatments that will make a positive impact on the lives of patients with Alzheimer's and Parkinson's disease. Mission's scientists have developed impressive early research toward the understanding of thes... |
Commenting on the collaboration, Dr Anker Lundemose, Mission CEO said: "AbbVie is one of the world's leading biopharmaceutical companies, therefore having them as our first major collaborator is a great validation of our science. It also marks a significant milestone in our strategic aim of realising some of the value ... |
He added, "The AbbVie team brings complementary capabilities and expertise as well as finance, and we greatly anticipate working with them. Together we can advance the development of Mission's best-in-class, DUB technology platform to find effective treatments for these unmet neurodegenerative diseases." |
No financial details have been disclosed. Under the terms of the agreement, both parties will collaborate during the research stage to identify specific DUBs and discover suitable compounds. AbbVie will then have the option to gain exclusive rights to develop and commercialize DUB inhibitors against up to four selected... |
The collaboration does not include any of Mission's lead DUB programs including USP30 and USP10. |
ENDS |
FOR MORE INFORMATION: |
Mission Therapeutics Ltd<br>Anker Lundemose MD PhD<br>Chief Executive Officer<br>Tel: +44 (0)1223 607 340 |
Instinctif Partners<br>Melanie Toyne-Sewell / Eileen Paul<br>Tel: +44 (0) 20 7457 2020<br>missiontherapeutics@instinctif.com |
Abbvie<br>Adelle Infante, Director External Communications<br>Tel: +1 847-938-8745<br>adelle.infante@abbvie.com |
NOTES TO EDITORS: |
About Mission Therapeutics |
Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, rare mitochondrial diseases, fibrosis and inflammation. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that ... |
Mission has strong links with key academic and research centers, including leading UK centres in neurodegenerative diseases as well as Prof. Jackson's Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute. The Company is managed by a team with broad international, commercial and clinical-scien... |
In February 2016, the Company completed an $86m financing that was led by Imperial Innovations (now part of IP Group) and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2... |
For more information about Mission, visit us at www.missiontherapeutics.com <br>Follow@MISSIONTherapeu on twitter, or LinkedIn. |
About AbbVie |
AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatment... |
For more information about AbbVie, please visit us at www.abbvie.com .<br>Follow @abbvie on Twitter, Facebook, or LinkedIn. |
Confidential EXECUTION VERSION |
COLLABORATION AND OPTION TO LICENSE AGREEMENT between PLEXIUM, INC. and ABBVIE GLOBAL ENTERPRISES LTD. Dated as of October 12, 2021 |
WEST\294499377.15 |
TABLE OF CONTENTS |
ARTICLE 1 DEFINITIONS .................................................................................................................. 1 |
ARTICLE 2 GOVERNANCE ............................................................................................................. 18 |
2.1 Joint Research Committee ............................................................................................................. 18 |
2.2 General Provisions Applicable to Joint Research Committee ....................................................... 19 |
2.3 Interactions Between the Joint Research Committee and Internal Teams ..................................... 20 |
2.4 Working Groups ............................................................................................................................ 20 |
2.5 Expenses ........................................................................................................................................ 20 |
ARTICLE 3 RESEARCH .................................................................................................................... 21 |
3.1 Research Plans ............................................................................................................................... 21 |
3.2 Performance of the Research Plans ............................................................................................... 21 |
3.3 Amendments to Research Plans .................................................................................................... 22 |
3.4 Substitute Research Program ......................................................................................................... 22 |
3.5 Interim Development Reports ....................................................................................................... 23 |
3.6 Option Data Packages .................................................................................................................... 23 |
3.7 Expenses ........................................................................................................................................ 24 |
3.8 Completion of Research Plans After Exercise of License Option ................................................. 24 |
3.9 Manufacturing in Support of Research Plan .................................................................................. 24 |
3.10 Technology Transfer ..................................................................................................................... 24 |
3.11 Regulatory Matters ........................................................................................................................ 25 |
3.12 Data Security and Privacy ............................................................................................................. 26 |
ARTICLE 4 LICENSE OPTION ........................................................................................................ 26 |
4.1 License Option Grant to AbbVie ................................................................................................... 26 |
4.2 Exercise of the License Option ...................................................................................................... 26 |
4.3 Consequences of Exercise ............................................................................................................. 26 |
4.4 HSR ............................................................................................................................................... 26 |
4.5 Termination of License Option...................................................................................................... 27 |
ARTICLE 5 DEVELOPMENT AND COMMERCIALIZATION AFTER LICENSE OPTION EXERCISE .................................................................................. 27 |
5.1 In General ...................................................................................................................................... 27 |
5.2 Diligence........................................................................................................................................ 27 |
5.2 Diligence........................................................................................................................................ 27 |
5.3 Cost-Sharing Option ...................................................................................................................... 28 |
5.4 Regulatory Matters ........................................................................................................................ 29 |
5.5 Booking of Sales; Distribution ...................................................................................................... 30 |
5.6 Product Trademarks ....................................................................................................................... 30 |
ARTICLE 6 GRANT OF RIGHTS..................................................................................................... 30 |
6.1 Grants to AbbVie on the Effective Date ........................................................................................ 30 |
6.2 Grants to AbbVie on the License Option Effective ....................................................................... 31 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.